SCHEMBL7163573

SCHEMBL7163573

OCC1OCc2ccccc21.OCc1ccc2c(c1)COC2c1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 3/20 0.39
PRCP P42785 1/20 0.32
SLC6A2 P23975 3/20 0.31
SLC6A4 P31645 3/20 0.31
NAMPT P43490 1/20 0.31
HTR1A P08908 1/20 0.31
ADRA2A P08913 1/20 0.31
DRD2 P14416 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
DRD1 P21728 1/20 0.31
DRD4 P21917 1/20 0.31
ADRA1D P25100 1/20 0.31
HTR2A P28223 1/20 0.31
ADRA1A P35348 1/20 0.31
ADRA1B P35368 1/20 0.31
DRD3 P35462 1/20 0.31
HTR2B P41595 1/20 0.31
SLC5A1 P13866 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4622856 0.87 SLC5A2 (0.40) SLC5A2SLC6A2SLC6A4NAMPTSLC5A1
SCHEMBL27508666 0.86 SLC5A2 (0.38) SLC5A2PRCPNAMPTSLC5A1
SCHEMBL4837968 0.78 PRCP (0.46) PRCPSLC6A2SLC6A4ADRA2BADRA2C
SCHEMBL4620798 0.75 SLC5A2 (0.35) SLC5A2SLC6A2SLC6A4HTR2AHTR2B
SCHEMBL4622359 0.75 LOXL2 (0.46) SLC5A2SLC6A2SLC6A4ADRA2AADRA2B
SCHEMBL9682302 0.74 ADRA2A (0.40) SLC5A2SLC6A2SLC6A4HTR1AADRA2A
SCHEMBL17193852 0.74 ADRA2A (0.40) SLC5A2SLC6A2SLC6A4HTR1AADRA2A
SCHEMBL9683908 0.74 LMNA (0.40) SLC6A2SLC6A4ADRA2AADRA2BADRA2C
SCHEMBL17193848 0.74 LMNA (0.40) SLC6A2SLC6A4ADRA2AADRA2BADRA2C
SCHEMBL17193849 0.74 LMNA (0.40) SLC6A2SLC6A4ADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030114692-A1 Method for the preparation of citalopram H. LUNDBECK A/S (DK) 2003-06-19 US disclosed
US-20030083508-A1 Method for the preparation of citalopram H. LUNDBECK A/S (DK) 2003-05-01 US disclosed
EP-1259500-A1 METHOD FOR THE PREPARATION OF CITALOPRAM H. Lundbeck A/S (DK) 2002-11-27 EP disclosed
US-20020004604-A1 Method for the preparation of citalopram H. LUNDBECK A/S (DK) 2002-01-10 US disclosed
WO-2001062754-A1 METHOD FOR THE PREPARATION OF CITALOPRAM H. LUNDBECK A/S (DK) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083508-A1 Method for the preparation of citalopram MAOB, MAOA, TPH1 SLC5A2 195/4885PRCP 675/4885SLC6A2 5/4885
US-20020004604-A1 Method for the preparation of citalopram MAOB, MAOA, TPH1 SLC5A2 195/4885PRCP 675/4885SLC6A2 5/4885
US-20030114692-A1 Method for the preparation of citalopram MAOB, MAOA, TPH1 SLC5A2 195/4885PRCP 675/4885SLC6A2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.